CoChat

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index; 18 of the 49 sources its claims cite were checked for support.

Diagnosis of mast cell activation syndrome: a global "consensus-2"

Open access

Abstract

The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of "mast cell activation syndrome" (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a "consensus" (re-termed here as "consensus-1"). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as "consensus-2"), resembling "consensus-1" in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by "consensus-2" criteria has potential to be problematic, but underdiagnosis by "consensus-1" criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.

Overview

CoChat Summary

TL;DR

The paper reviews two main proposals for diagnosing mast cell activation syndrome (MCAS), termed consensus-1 and consensus-2, and argues that either is valid, reasonable, and helpful until more definitive research is available. It emphasizes that underdiagnosis by restrictive criteria is a larger concern than overdiagnosis, given prevalence estimates up to 17% and frequent treatment response.

Key findings

  • Two principal diagnostic proposals exist: consensus-1 (Valent et al., originally 2010/2012, updated 2019) and consensus-2 (Molderings et al., originally 2011, updated 2017); they differ substantially in the number of patients qualifying for diagnosis and thus treatment.
  • MCAS prevalence estimates range from “rare” to as high as 17% of the general population; allergy prevalence is cited as 10–50%, and hereditary alpha-tryptasemia (HAT) is estimated at approximately 4–6% of the population.
  • Consensus-2 considers a wider range of symptoms and mediators (tryptase, chromogranin A, heparin, PGD2, histamine, N-MH, 11-β-PGF2α, LTE4), while consensus-1 emphasizes a “20% + 2” tryptase rise and requires at least partial response to antihistamines and/or cromolyn; elevated plasma heparin is reported in approximately 80% of patients clinically demonstrating MCA symptoms when measured with a sufficiently sensitive assay.
  • HAT appears to fit within the MCAS spectrum, with no prognostic or management differences yet identified; TPSAB1 testing is suggested mainly for investigative settings and for persistent mild tryptase elevation (e.g., ≤20 ng/mL).

Methods

  • Literature search as of October 27, 2019: PubMed “mast cell activation syndrome” yielded 138 articles and Google Scholar yielded 1410; nine publications offering new or modified diagnostic schemes were identified and grouped into two principal schools of thought.
  • Searches for “hereditary alpha-tryptasemia” and “TPSAB1” yielded 1 and 150 articles on PubMed and 44 and 847 on Google Scholar, respectively; principal papers and selected others were read.
  • The analysis assessed each diagnostic school for validity of diagnostic criteria, diagnostic accuracy, and practicality; no primary data collection or new patient study was performed.

Limitations

  • Stated: no study has yet compared the validity of any one MCAS diagnostic criteria proposal against any other, and no large-scale studies of MCAS aspects exist; the two proposals produce incomparable patient populations for research.
  • Stated: MCAS is extraordinarily complex and heterogeneous, routine somatic mutational profiling in mast cells is unavailable, and the HAT definition is challenged by findings that about 8% of patients with redundant TPSAB1 have no tryptase elevation.
  • Evident: this is a consensus/opinion review authored largely by proponents of consensus-2, not an empirical validation study, so its recommendations reflect that perspective.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1515/dx-2020-0005

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 9 Not valid · 12 Not checked · 40 Own results and interpretations

29 more claims · 2 with their cited sources checked

Create a free account to see all 72 claims and to verify the 8 references still open.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 30

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 96 references

Cited by

See all 115

Metadata

Authors
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., McCann, K. K., McKee, D. L., Menk Otto, L., Pace, L. A., Perkins, D. D., Radovsky, L., Raleigh, M. S., Rapaport, S. A., Reinhold, E. J., Renneker, M. L., Robinson, W. A., Roland, A. M., Rosenbloom, E. S., Rowe, P. C., Ruhoy, I. S., Saperstein, D. S., Schlosser, D. A., Schofield, J. R., Settle, J. E., Weinstock, L. B., Wengenroth, M., Westaway, M., Xi, S. C., & Molderings, G. J.
Affiliations
  • Armonk Integrative Medicine , Purchase, NY , USA
  • My Passion 4 Health , Tucson , AZ , USA
  • Medical College of Wisconsin (US)
  • Plaza Infectious Disease , Kansas City , MO , USA
  • Alaska Internal Medicine and Pediatrics , Anchorage , AK , USA
  • Peachtree Allergy and Asthma , Atlanta , GA , USA
  • Beaver Medical Group (US)
  • University of Kentucky (US)
  • Complex Cares, LLC , Shoreview , MN , USA
  • Allergy and Asthma Specialists of Cadillac , Cadillac , MI , USA
  • Oregon Health & Science University (US)
  • Healing Dragon, Portland , OR , USA
  • Hoffman Centre for Integrative and Functional Medicine , Calgary , Alberta , Canada
  • Center for Complex Diseases , Mountain View , CA , USA
  • CHI Health (US)
  • Healthwell Physical Therapy Group , San Francisco , CA , USA
  • Heart of the Valley Pediatric Cardiology , Pleasanton , CA , USA
  • The Spring Center , Costa Mesa , CA , USA
  • Integrative Cancer Consulting, Aptos , CA , USA
  • Helfgott Research Institute , National College of Natural Medicine , Portland , OR , USA
  • University of Utah (US)
  • Elevate Health , Portland , OR , USA
  • St. Paul , MN , USA
  • Restoration Healthcare , Irvine , CA , USA
  • Haven Medical , Chapel Hill , NC , USA
  • Royal College of General Practitioners (GB)
  • University of California, San Francisco (US)
  • University of Colorado Denver (US)
  • Sacramento , CA , USA
  • Johns Hopkins University (US)
  • Center for Healing Neurology , Seattle , WA , USA
  • Center for Complex Neurology, EDS and POTS , Phoenix , AZ , USA
  • Patient Navigator, LLC , Reston , VA , USA
  • University of Colorado Anschutz (US)
  • Washington University in St. Louis (US)
  • University of Lübeck (DE)
  • Westaway Medical , Brisbane , Queensland , Australia
  • University of Southern California (US)
  • University Hospital Bonn (DE)
Corresponding author
Afrin, Lawrence B.
Venue
Diagnosis
Published
2020-04-22
Volume
8
Issue
2
Pages
137-152
ISSN
  • 2194-8011 (ISSN-L)
  • 2194-802X
OpenAlex
W3020152139
Cited by
115
References
97
Citations by year
2026: 19 · 2025: 13 · 2024: 15 · 2023: 21 · 2022: 24 · 2021: 17 · 2020: 5
FWCI
1.64
Type
journal article
Language
en
Open access
Locations
  • Diagnosis (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
Funders
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD085852)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Mast cells and histamine
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
mast cell activation syndrome, diagnostic criteria, mast cell activation, overdiagnosis, underdiagnosis, mastocytosis
MeSH terms
Consensus Statements as Topic, Humans, Mast Cells, Mastocytosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis of mast cell activation syndrome: a global "consensus-2". https://app.cochat.ai/papers/10.1515/dx-2020-0005
The paper
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., Dubravec, M. S., Guggenheim, A. G., Hindman, K. J., Hoffman, B., Kaufman, D. L., Kratzer, S. J., Lee, T. M., Marantz, M. S., Maxwell, A. J., . . . Molderings, G. J. (2021). Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis. https://doi.org/10.1515/dx-2020-0005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.